Vaderis Therapeutics raised a Series B to run a Phase 3 study of its AKT inhibitor engasertib in a rare blood disorder called hereditary hemorrhagic telangiectasia.
Lei Lei Wu is a News Reporter at Endpoints News. She specializes in reporting on cell therapy, genetic medicines, and the science behind drug development, with a keen interest in healthcare technology and pharmaceuticals. Lei Lei's work is featured in Endpoints News, where she also covers medical meetings and analyzes the latest clinical trial results.